Curative Biotechnology Stock Current Valuation
| CUBT Stock | USD 0.01 0.0001 1.15% |
Valuation analysis of Curative Biotechnology helps investors to measure Curative Biotechnology's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. Enterprise Value is likely to gain to about 17.1 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (6.84) in 2024. Fundamental drivers impacting Curative Biotechnology's valuation include:
Enterprise Value 10.3 M | Enterprise Value Ebitda (3.88) | Price Sales 158.5303 |
Fairly Valued
Today
Please note that Curative Biotechnology's price fluctuation is out of control at this time. Calculation of the real value of Curative Biotechnology is based on 3 months time horizon. Increasing Curative Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Curative Biotechnology's intrinsic value may or may not be the same as its current market price of 0.01, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.0088 | Real 0.008448 | Hype 0.01 |
The intrinsic value of Curative Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Curative Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Curative Biotechnology helps investors to forecast how Curative stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Curative Biotechnology more accurately as focusing exclusively on Curative Biotechnology's fundamentals will not take into account other important factors: Curative Biotechnology Company Current Valuation Analysis
Curative Biotechnology's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Curative Biotechnology Current Valuation | 10.3 M |
Most of Curative Biotechnology's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Curative Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Curative Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Curative Biotechnology is extremely important. It helps to project a fair market value of Curative Stock properly, considering its historical fundamentals such as Current Valuation. Since Curative Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Curative Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Curative Biotechnology's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Curative Biotechnology has a Current Valuation of 10.3 M. This is 99.93% lower than that of the Biotechnology sector and 99.78% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.94% higher than that of the company.
Curative Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Curative Biotechnology's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Curative Biotechnology could also be used in its relative valuation, which is a method of valuing Curative Biotechnology by comparing valuation metrics of similar companies.Curative Biotechnology is currently under evaluation in current valuation category among its peers.
Curative Biotechnology Current Valuation Drivers
We derive many important indicators used in calculating different scores of Curative Biotechnology from analyzing Curative Biotechnology's financial statements. These drivers represent accounts that assess Curative Biotechnology's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Curative Biotechnology's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 726.3K | 9.9M | 26.1M | 11.4M | 14.1M | 14.8M | |
| Enterprise Value | 726.4K | 10.3M | 25.4M | 12.5M | 16.3M | 17.1M |
Curative Fundamentals
| Return On Equity | -3.98 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 10.3 M | ||||
| Shares Outstanding | 903.26 M | ||||
| Shares Owned By Insiders | 0.05 % | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| Gross Profit | 100.21 K | ||||
| EBITDA | (2.5 M) | ||||
| Net Income | (3.96 M) | ||||
| Cash And Equivalents | 126.85 K | ||||
| Total Debt | 2.26 M | ||||
| Debt To Equity | 6.60 % | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0) X | ||||
| Cash Flow From Operations | (486.58 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Beta | 214.95 | ||||
| Market Capitalization | 9.03 M | ||||
| Total Asset | 2.6 M | ||||
| Retained Earnings | (38.23 M) | ||||
| Working Capital | (4.42 M) | ||||
| Net Asset | 2.6 M |
About Curative Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Curative Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curative Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curative Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.